The DOI matches its Crossref record; 40 of the 42 references it cites were found in a registry or an index.
Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus
Open accessAbstract
Summary: Aim : To determine the efficacy and tolerability of sibutramine hydrochloride in obese patients whose type 2 diabetes was poorly controlled on diet alone or with an oral antidiabetic agent Methods : This study was a 24‐week, double‐blind, multicentre trial following a 5‐week placebo run‐in period. One hundred and seventy‐five obese (body mass index (b.m.i.) ≥27 kg/m 2 ) patients with poorly controlled type 2 diabetes mellitus were randomized either to sibutramine (n = 89; mean age 53.5 years; mean weight 99.3 kg) or placebo (n = 86; mean age 55 years; mean weight 98.2 kg) at 16 participating centres. To achieve moderate calorie restriction (deficit ≥ 250–500 kcal/day), individual dietary counselling was accompanied by either placebo or sibutramine (initial dosage of 5 mg/day titrated up by 5 mg biweekly through week 6, and maintained at 20 mg through week 24). The main outcome measures included changes in weight, b.m.i., waist and hip circumference, glycaemic control, lipid profile, and quality of life, and evaluation of reported adverse events. Results : Sixty‐seven per cent of sibutramine patients and 71% of placebo patients completed the study. At week 24 when comparing those who completed the course, sibutramine compared with placebo patients showed significantly greater (p < 0.001) absolute (−4.3 vs. −0.4 kg) and percentage (−4.5% vs. −0.5%) weight loss. Weight loss ≥5% or 10% was achieved by 33% and 8% of sibutramine patients, respectively, but no placebo patients (p < 0.03 or better). Improvement in glycaemic control was correlated with weight loss (p < 0.001). In 5% and 10% weight‐loss responders, mean treatment differences were −0.53% and −1.65% (p ≤ 0.05), respectively, for HbA 1c , and −1.4 mmol/l (p ≤0.05) and −3.8 (p ≤0.05) mmol/l for fasting plasma glucose. Sibutramine patients also showed improvements in fasting insulin, triglycerides, HDL cholesterol, and quality‐of‐life assessments. Overall, sibutramine was well tolerated compared with the placebo. Sibutramine treatment was associated with small mean increases in blood pressure (BP) and pulse, although an increase in BP was not seen in sibutramine‐treated patients who lost ≥ 5% of their weight. Conclusions : Sibutramine produced statistically and clinically significant weight loss when used in combination with recommendations for moderate caloric restriction. This weight loss was associated with improvements in metabolic control and quality of life, and sibutramine was generally well tolerated in obese patients with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pharmacotherapy with the two currently approved drugs for obesity treatment, orlistat (a gastrointestinal lipase inhibitor) and sibutramine (a monoamine reuptake inhibitor), have both been associated with weight loss, improvements in serum lipids, and insulin sensitivity (76, 109, 270).”
From Cardiac remodeling in obesity (2008) · cites this paper as [109]
In the citing paper
“Orlistat treatment usually reduces blood pressure, while sibutramine is commonly associated with increased heart rate and blood pressure (109, 393).”
From Cardiac remodeling in obesity (2008) · cites this paper as [109]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
An analysis of variance test for normality (complete samples)
SHAPIRO, S. S., & WILK, M. B. (1965) · Biometrika · doi:10.1093/biomet/52.3-4.591 · Cited by 23,480
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,453
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
Harris, M. I., Flegal, K. M., Cowie, C. C., Eberhardt, M. S., Goldstein, D. E., Little, R. R., Wiedmeyer, H.-M., & Byrd-Holt, D. D. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.518 · Cited by 2,703
Pouliot, M., Després, J., Lemieux, S., Moorjani, S., Bouchard, C., Tremblay, A., Nadeau, A., & Lupien, P. J. (1994) · The American Journal of Cardiology · doi:10.1016/0002-9149(94)90676-9 · Cited by 2,099
Sjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11509-4 · Cited by 1,237
Davidson, M. H., Hauptman, J., DiGirolamo, M., Foreyt, J. P., Halsted, C. H., Heber, D., Heimburger, D. C., Lucas, C. P., Robbins, D. C., Chung, J., et al. (1999) · JAMA · doi:10.1001/jama.281.3.235 · Cited by 947
Hollander, P. A., Elbein, S. C., Hirsch, I. B., Kelley, D., McGill, J., Taylor, T., Weiss, S. R., Crockett, S. E., Kaplan, R. A., Comstock, J., et al. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1288 · Cited by 654
Research works printed but not linked: 11
- Albu J, 1995, Weight control: metabolic and cardiovascular effects, Diabetes Rev, 3, 335
- Halford JCG, 1994, Effects in the rat of sibutramine on food intake and the behavioural satiety sequence [abstract], Br J Pharmacol, 114, 387P
- Heath MJ, 1999, Sibutramine enhances weight loss and improves glycemic control and plasma lipid profile in obese patients with type 2 diabetes mellitus [abstract], Diabetes, 48, A308
- Olkin I, 1960, Contributions to Probability and Statistics: Essays in Honor of Harold Hotelling. Stanford, CA.
- 10.2337/diab.35.2.155 · DOI
- 10.1001/archinte.148.4.873 · DOI
- Wynne RD, 1997, A single‐dose, placebo‐controlled, comparative evaluation of the cardiovascular effects of sibutramine and amitriptyline in normal volunteers, Int J Pharmaceut Med, 11, 65
- Goldstein DJ, 1992, Fluoxetine in obese patients with noninsulin‐dependent diabetes mellitus [abstract], Clin Res, 40, 240A
- Griffiths J, 1998, Sibutramine in the treatment of overweight non‐insulin dependent diabetics [abstract O72], Int J Obes Relat Metab Disord, 19, 41
- Griffiths J, 1995, Body composition changes following weight loss induced by sibutramine [abstract P395], Int J Obes Relat Metab Disord, 19, 144
- Yip I, 1998, Sibutramine reduces visceral fat, leptin, and estradiol level in obese women, FASEB, 12, A353
Cited by
Sorted by citations
Items 201–244 of 244
Management of the Obese Patient
Roth, J. L., & Doerfler, B. (2007) · Clinical Gastroenterology · doi:10.1007/978-1-59745-320-2_9
Treatment of the Metabolic Syndrome with Weight Loss, Exercise, Hormones, and Surgery
Bray, G. A. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-116-5_4
“In a 24-week trial, the dose of sibutramine was increased from 5 mg to 20 mg per day over 6 weeks ( 42 ).”
BackgroundAhima, R. S. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1607-5_19
Sánchez, O., & Ruiz, J. S. (2008) · Medicina Clínica · doi:10.1157/13116324
Tratamiento farmacológico de la obesidad
Valls, J. F. M., & Rodríguez, R. C. (2002) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(02)70863-9
Modulació farmacològica de l'oleoil-estrona sobre la ingesta i la composició corporal
Lorente, R. F. (2007) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Obesity and Its Medical Management
Gandikota, P., Chernoff, A., & Anastasopoulou, C. (2009)
Obesity and Cardiac Dysfunction
Sweeney, G., Litwin, S. E., & Abel, E. D. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1607-5_14
Maggioni, L. (2014) · Americanae (AECID Library)
Patogeneticheskiy podkhod k lecheniyu ozhireniya i sakharnogo diabeta 2 tipa
Romantsova, T. I. (2008) · Obesity and metabolism · doi:10.14341/2071-8713-5220
OBESE DIABETIC PATIENTS: IMPACT OF DIFFERENT MANAGEMENT MODALITIES
Dampanaboina, K., Bitra, V. R., & Annapurna, A. (2012) · Iranian journal of diabetes and obesity
Obesidade - Revisão Bibliográfica
da Saúde, C. (2011)
Nutritional Strategies for Patients with Obesity and the Metabolic Syndrome
Kushner, R. F., & Roth, J. L. (2006) · Nutrition and disease prevention · doi:10.1201/9781420014884.ch4
Insulin Resistance Syndrome and Its Vascular Complications
Thethi, T. K., Bratcher, C., Mallik, T., & Fonseca, V. A. (2007) · CRC Press eBooks · doi:10.3109/9780849379581-26
Treating the Morbidly Obese Patient
Taylor, J. E., Pyle, S. A., Poston, W. S. C., & Foreyt, J. P. (2005) · CRC Press eBooks · doi:10.3109/9780203025758-4
Pharmacologic Therapy for Obesity and Overweight in Adults and Adolescents
Aronne, L. J., & Thearle, M. S. (2006) · CRC series in modern nutrition science · doi:10.1201/9781420004649.ch6
Individual interventions to treat obesity
Townsend, N. P., & Scriven, A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-7020-4634-6.00005-4
Pharmacologic Agents in the Treatment of Obesity
Ryan, D. H. (2006) · Medical psychiatry · doi:10.3109/9780849374517.012
Buranapin, S., & Apovian, C. M. (2006) · Fundamental and clinical cardiology · doi:10.3109/9781420018905.013
Corrêa, L. L., Platt, M. W., Carraro, L., Moreira, R. O., Faria, R., Godoy‐Matos, A. F., Póvoa, L. C., Appolinário, J. C., & Coutinho, W. F. (2005)
Tratamento medicamentoso atual Current obesity drug treatment
Mancini, M. C., & Halpern, A. (2006)
Warkentin, L. M. (2014) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r31v5bm3b
Sharma, A. M. (2002) · doi:10.1002/9780470986882.ch19
Venkataraman, H., & McKay, G. (2009) · Practical Diabetes · doi:10.1002/pdi.1426
Is there any conclusive evidence that exercise alone reduces glucose intolerance?
Astrup, A. V. (2003) · The British Journal of Diabetes · doi:10.1177/1474651403003001s0501
Development of protocols to identify high hunger and low satiety phenotypes
Elfarssi, H. M. (2019) · Sheffield Hallam University · doi:10.7190/shu-thesis-00370
(2011) · CRC Press eBooks · doi:10.1201/b10790-15
(2014) · Elsevier eBooks · doi:10.1016/b978-0-7020-4634-6.09985-4
Greenway, F. L., & Gupta, A. (2007) · CRC Press eBooks · doi:10.1201/9781420005479.pt5
Nauck, M. A. (2003) · Springer eBooks · doi:10.1007/978-3-642-55896-2_47
Wilding, J. P. H. (2008) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-7425-9_5
Diabetic neuropathy - a continuing enigma
Sugimoto, K., Murakawa, Y., & Sima, A. A. F. (2000) · Diabetes/Metabolism Research and Reviews · doi:10.1002/1520-7560(200011/12)16:6 · Cited by 188
Noradrenergic, Serotonergic, Antiepileptic, and Herbal Drugs
Bray, G. A. (2004) · CRC Press eBooks · doi:10.1201/9780203508756.ch13
Kim, Y.-J., Cho, S.-P., Lee, H.-J., Hong, G.-L., Kim, K., Ryu, S., & Jung, J. (2022) · Journal of Korean Medicine for Obesity Research · doi:10.15429/jkomor.2022.22.1.30
Asif, M. (2023) · Journal of Bacteriology & Mycology Open Access · doi:10.15406/jbmoa.2023.11.00346
Pharmacological Approaches to the Treatment of Obesity
Bray, G. A. (2012) · Wiley eBooks · doi:10.1002/9781394323142.ch18
Fixed Combination Anti-obesity Medications
Garcha, S. C., & Kalra, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1651-0_3
The Medical Management of Obesity
March, V., & Pierce, K. (2007) · Springer eBooks · doi:10.1007/978-0-387-68062-0_2
Weight Loss Medications and the Metabolic Syndrome
Buckley, L. L., & Berressen, D. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-192-5_16
“In a study by Fujioka, sibutramine produced a 5% weight loss in 25% of subjects and 10% weight loss in a little more than 5% of patients ( 39 ) . This study demonstrates what has been seen with other weight-loss approaches: specifically, it appears to be more difficult to produce weight loss in people with type 2 diab…”
ResultInfluentialEfeitos do tratamento com sibutramina sobre a qualidade espermática de ratos machos Wistar
Borges, C. D. S. (2013) · Aleph UCLA Undergraduate Research Journal for the Humanities and Social Sciences
Orlistat and Sibutramine in the Management of Obesity
Wyatt, H. R. (2007) · Springer eBooks · doi:10.1007/978-0-387-32164-6_15
“Sibutramine has been evaluated extensively in multiple clinical trials lasting 8 weeks to 24 months in healthy obese adults and overweight and obese adults with a cardiovascular risk factor (hypertension, type 2 diabetes, or dyslipidemia [41–56]).”
Background
Metadata
- Authors
- Fujioka, K., Seaton, T. B., Rowe, E., Jelinek, C. A., Raskin, P., Lebovitz, H. E., Weinstein, S. P., & Group, T. S. C. S.
- Affiliations
- Scripps Health (US)
- The University of Texas Southwestern Medical Center (US)
- State University of New York (US)
- Corresponding author
- Fujioka, K.
- ORCID
- Fujioka, K.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2000-05
- Volume
- 2
- Issue
- 3
- Pages
- 175-187
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2032907323
- Cited by
- 244
- References
- 42
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 2 · 2022: 5 · 2021: 4 · 2020: 4 · 2019: 5 · 2018: 3 · 2017: 7 · 2016: 7 · 2015: 4 · 2014: 8 · 2013: 7 · 2012: 3
- FWCI
- 11.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Obesity and Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- sibutramine, type 2 diabetes, obesity, weight loss, glycemic control, HbA1c, fasting blood glucose, lipid profile, quality of life, adverse events, appetite suppressants, nutrition counseling, caloric restriction, drug efficacy and tolerability, body mass index, waist and hip circumference
- MeSH terms
- Adolescent, Adult, Aged, Appetite Depressants, Blood Pressure, Cyclobutanes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diet, Reducing, Double-Blind Method, Female, Humans, Hyperglycemia, Lipids, Male, Middle Aged, Obesity, Quality of Life, Weight Loss, Body Mass Index, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
